Page last updated: 2024-11-05

thalidomide and Shock

thalidomide has been researched along with Shock in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Shock: A pathological condition manifested by failure to perfuse or oxygenate vital organs.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Urata, K1
Brault, A1
Rocheleau, B1
Huet, PM1

Other Studies

1 other study available for thalidomide and Shock

ArticleYear
Role of Kupffer cells in the survival after rat liver transplantation with long portal vein clamping times.
    Transplant international : official journal of the European Society for Organ Transplantation, 2000, Volume: 13, Issue:6

    Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Allopurinol; Animals; Calcium Channel Blockers; Cell C

2000